<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>COIN Studies Overview &#8211; Cell Free DNA</title>
	<atom:link href="https://cfdna.nl/category/coin-studies-overview/feed/" rel="self" type="application/rss+xml" />
	<link>https://cfdna.nl</link>
	<description>Grensverleggende innovatie in oncologische biomarker diagnostiek</description>
	<lastBuildDate>Fri, 21 Jan 2022 12:47:52 +0000</lastBuildDate>
	<language>nl-NL</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
	<item>
		<title>high risk stage II CC patients after surgery</title>
		<link>https://cfdna.nl/high-risk-stage-ii-cc-patients-after-surgery/</link>
		
		<dc:creator><![CDATA[Insignia1144]]></dc:creator>
		<pubDate>Fri, 21 Jan 2022 12:38:55 +0000</pubDate>
				<category><![CDATA[COIN Studies Overview]]></category>
		<guid isPermaLink="false">https://cfdna.nl/?p=21286</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[<div class="wpb-content-wrapper"><div class="vc_row wpb_row vc_row-fluid"><div class="wpb_column vc_column_container vc_col-sm-12"><div class="vc_column-inner "><div class="wpb_wrapper">
	<div class="wpb_text_column wpb_content_element " >
		<div class="wpb_wrapper">
			<p class="p1"><span class="s1"><span class="dropcap insignia-dropcap dropcap-square  dropcap-normal">D</span></span></p>
<p class="p1"><span class="s1">Research question: ctDNA analysis is used for the selection of high risk stage II CC patients after surgery. ctDNA positive patients are randomized after surgery for adjuvant chemotherapy or standard of care (no adjuvant treatment)</span></p>

		</div>
	</div>
<blockquote id="ins-blockquotes-69e9c25c6e1c0" class="ins-blockquotes ins-blockquotes text-left pc-border " ><q style="color: #074575">MEDOCC-CrEATE : Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating<br />
tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.</q></blockquote><script type="text/javascript">
		(function(jQuery) {jQuery("head").append("<style>#ins-blockquotes-69e9c25c6e1c0.ins-blockquotes {background-color: #f3f7f9;}</style>")
					})(jQuery);
						</script>
	<div class="wpb_text_column wpb_content_element  vc_custom_1642769269890" >
		<div class="wpb_wrapper">
			<div class="page" title="Page 2">
<div class="section">
<div class="layoutArea">
<div class="column">
<p>Research question: ctDNA analysis is used for the selection of high risk stage II CC patients after surgery. ctDNA positive patients are randomized after surgery for adjuvant chemotherapy or standard of care (no adjuvant treatment)</p>
<p>Patients to be included: 1320<br />
Nr. of patients with ctDNA samples: 660<br />
Nr of ctDNA samples: 660<br />
Study design: interventional trial<br />
Tumor type: Colon Caner, stage II<br />
Application of ctDNA: Recurrence risk after surgery</p>
<p>Contact person(s): Prof. M. Koopman (UMCU), Dr G. Vink (UMCU), Dr. Remond Fijneman (NKI-AVL)</p>
<p class="p1">Source</p>
</div>
</div>
</div>
</div>

		</div>
	</div>
</div></div></div></div>
</div>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
